Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti- carcinoembryonic antigen murine monoclonal antibody IgG

Journal of Nuclear Medicine

Volumn 38, Issue 6, 1997, Pages 858-870

  Behr, Thomas M ^a   Sharkey, Robert M ^a   Juweid, Malik E ^a   Dunn, Robert M ^a   Vagg, Rae C ^a   Ying, Zhiliang ^a   Zhang, Cun H ^a   Swayne, Lawrence C ^a   Vardi, Yehuda ^a   Siegel, Jeffry A ^a   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Iodine 123 anti CEA; Pharmacokinetics; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 131; IODINE 131; NP 4; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CANCER; BONE MARROW TOXICITY; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DOSIMETRY; DRUG TUMOR LEVEL; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RISK ASSESSMENT; SALIVARY GLAND CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BONE MARROW; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030952706     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Sikorska HM, Fuks A, Gold P. Carcinoembryonic antigen. In: Sell S, ed. Serological cancer markers. Totowa, NJ: Humana Press, 1992:47-97.
2. Chabner BA, DeVita VT, Hellman S, Rosenberg SA, eds. Anticancer drugs. Cancer: principles and practice of oncohg, 4th ed. Philadelphia: J. B. Lippincott, 1993:325-417.
3. DeVita VT, Hellman S, Rosenberg SA, eds. Biological therapy of cancer. Philadelphia: J. B. Lippincott, 1991.
4. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to Carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384-1388.
5. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-499.
6. Goldenberg DM, ed. Cancer imaging with radiolabeled antibodies. Boston: Kluwer Academic Publishers, 1990.
7. Goldenberg DM, ed. Cancer therapy with radiolabeled antibodies. Boca Raton, FL: CRC Press, 1995.
8. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet 1995;346:336-340.
9. Jain RK, Baxter LT. Mechanisms of heterogenous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:7022-7032.
10. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, Weinstein JN. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-5153.
11. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994;35:1017-1022.
12. Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983;43:686-692.
13. Sharkey RM, Goldenberg DM, Goldenberg H, et al. Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, targeting properties in humans. Cancer Res 1990;50:2823-2831.
14. Goldenberg DM, Wlodkowski TJ, Sharkey RM, et al. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med 1993;34:61-70.
15. 99mTc: the role of metabolism and kinetics. Cancer Res 1995;55(suppl): 5777s-5785s.
16. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1990;31:508-511.
17. Primus FJ, Kelley EA, Hansen HJ, Goldenberg DM. "Sandwich"-type immunoassay for carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and management of cancer. Clin Chem 1988;34:261-264.
18. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55(suppl):5935s-5945s.
19. Hansen HJ, Sullivan CL, Sharkey RM, Goldenberg DM. HAMA interference with murine monoclonal antibody-based immunoassays. J Clin Immunoassays 1993;16: 294-299.
20. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990;50(suppl):1039s-1042s.
21. Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Nucl Med Biol 1989;16:553-559.
22. Wu RK, Siegel JA. Absolute quantitation of radioactivity using the buildup factor. Med Phys 1984;11:189-192.
23. Dunn RM, Juweid ME, Behr TM, Siegel JA, Sharkey RM, Goldenberg DM. An automated internal dosimetry scheme for radiolabeled antibodies. Med Phys 1995;22: 1549-1550.
24. Behr TM, Sharkey RM, Juweid ME, et al. Factors influencing the phanmacokinetics. dosimetry and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of CEA-expressing tumors. Cancer Res 1996;56:1805-1816.
25. Schwartz MK. Lactic dehydrogenase: an old enzyme reborn as a cancer marker? Am J Clin Pathol 1991;96:441-443.
26. Losman MJ, DeJager RL, Monestier M, Sharkey RM, Goldenberg DM. Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies. Cancer Res 1990;50(suppl):1055s-1058s.
27. Ford EH, Lee RE, Sharkey RM, Alger EA, Horowitz JA, Hall TC, Goldenberg DM. Effect of human anti-mouse antibody (HAMA) on monoclonal antibody (Mab) biokinetics and biodistribution during a phase I/II radioimmunotherapy clinical trial [Abstract 87]. J Nucl Mad 1988;29:761.
28. Dhingra K, Fritsche H, Murray JL, et al. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 1995;55:3060-3067.
29. Hemando JJ, von Kleist S, Grunert F. A repertoire of monoclonal antibodies reveals extensive epitope heterogeneity in CEA purified from neoplasms originating from different organs. Int J Cancer 1994;56:655-661.
30. Thomas P, Toth CA, Saini KS, Jessup JM, Steele G. The structure, metabolism and function of the carcinoembryonic antigen gene family. Biochem Biophys Acta 1990:1032:177-189.
31. Wahl RL, Zasadny KR, Gates VL, Fisher SJ, Kaminski MS. Do tracer dosimetry studies predict therapy kinetic behavior in I-131 anti-B1 radioimmunotherapy? [Abstract]. J Nucl Med 1995;36(suppl):226P.
32. 131iodine activity. Results from a prospective, randomized multicenter study. Eur J Clin Invest 1995;25:186-193.
33. 131I-labeled monoclonal antibodies. Nucl Med Commun 1996;17:767-780.
34. Behr TM, Sharkey RM, Juweid ME, et al. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J Nucl Med 1997;38:409-418.
35. 131I-labeled monoclonal antibodies. Cancer Res 1992;52:6036-6044.
36. Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonie cancer xenografts. Cancer Res 1994;54:142-151.
37. Dunn RM, Juweid ME, Behr TM, Siegel JA, Sharkey RM, Goldenberg DM. Dosimetric potential of minimal residual disease using radiolabeled antibodies [Abstract]. J Nucl Med 1996;37(suppl):44P.